{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "be:HDL",
      "entity_text" : "HDL",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00528",
      "entity_text" : "GFT505",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Phase I studies in healthy volunteers showed that GFT505 at doses from 40 to 100 mg/day induces a dose dependent reduction in plasma triglyceride and an increase in HDL cholesterol.",
  "reading_complete" : "2020-07-28T12:01:24Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T11:54:55Z",
  "trigger" : "induces",
  "evidence" : [ "GFT505 at doses from 40 to 100 mg/day induces a dose-dependent reduction in plasma triglyceride and an increase in HDL" ],
  "pmc_id" : "3161281",
  "score" : 0
}